Friday, June 26, 2026 Never be the last to know Go Pro · $20/mo →
Inside MedSpa
The Daily Intelligence Brief · Medical Aesthetics
1 free article left this week. Subscribers read everything, unlimited.Subscribe →
Injectables

Letybo vs. Botox: Key Differences in Units, Onset, and Clinical Profile for Medspa Owners

Letybo and Botox are not interchangeable: they differ in potency, diffusion, onset speed, and market positioning—here's what owners need to know about unit equivalency and patient outcomes.

Letybo vs. Botox: Key Differences in Units, Onset, and Clinical Profile for Medspa Owners

Photo: cottonbro studio / Pexels

Letybo and Botox are not the same product, despite both being botulinum toxin type A formulations. They differ meaningfully in potency, diffusion profile, clinical onset, and cost structure—distinctions that matter for patient outcomes, unit economics, and competitive positioning.

Potency and Unit Equivalency

Letybo (Hugel, South Korea) and Botox (AbbVie/Allergan Aesthetics) are NOT unit-for-unit equivalent. Letybo is approximately 1:1.5 to 1:2 less potent than Botox on a per-unit basis, meaning you typically need more Letybo units to achieve the same clinical effect. A patient who receives 20 units of Botox for glabellar lines might require 25–30 units of Letybo to match efficacy. This is not a flaw in Letybo; it reflects different manufacturing, complexing proteins, and potency assay standards. The FDA does not mandate unit-to-unit equivalency across toxin brands—each is dosed independently based on its own clinical trial data and labeling.

Onset and Diffusion

Letybo has a slightly slower onset than Botox. Botox typically shows visible softening within 3–5 days, with full effect by day 10–14. Letybo onset is often reported at 5–7 days, with plateau effect by day 14–21. This difference is clinically modest but worth setting patient expectations correctly. Diffusion profiles also vary: Botox has a well-characterized, relatively tight diffusion zone due to its formulation and protein complex. Letybo's diffusion is comparable but not identical, which can subtly affect spread into adjacent musculature—a consideration if you're treating near the orbital rim or brow.

Market Positioning and Cost

Letybo requires 25–30% more units than Botox to achieve equivalent results, narrowing the per-treatment cost advantage despite lower per-unit pricing.

Letybo entered the U.S. market in 2023 and is positioned as a value alternative. Wholesale cost per unit is typically 15–25% lower than Botox, making it attractive for practices managing per-unit economics. However, because you need more units to match Botox effect, the total-dose cost advantage narrows. If Botox costs $12–14 per unit wholesale and Letybo costs $9–11 per unit, but you need 25% more Letybo units, the per-treatment material cost difference shrinks to roughly 5–10%. Letybo also lacks the rebate infrastructure of Allergan's Alle program or Galderma's Aspire loyalty network, which can offset per-unit pricing for high-volume practices.

Clinical Considerations for Owners

Patient retention depends on consistent results. Because Letybo onset is slower and potency differs, switching patients mid-treatment cycle can create dissatisfaction. If a patient has been receiving Botox every 12 weeks and you switch to Letybo at equivalent units, they may perceive delayed or diminished effect. Transparent communication—and potentially a trial period at adjusted dosing—is essential. Letybo is FDA-cleared for glabellar lines, crow's feet, and forehead lines, matching Botox's approved indications.

Supply and Regulatory Status

Letybo is FDA-cleared (510(k) pathway) and available through licensed wholesalers. It is not a compounded or gray-market product. Hugel has established U.S. distribution, though supply can be tighter than Botox during peak demand. Verify current availability and pricing with your wholesaler, as market dynamics shift.

The choice between Letybo and Botox is ultimately about patient expectations, practice economics, and supply reliability—not clinical equivalence.

Frequently asked questions

How many units of Letybo equal one unit of Botox?

Letybo is approximately 1:1.5 to 1:2 less potent than Botox per unit, meaning a patient who receives 20 units of Botox for glabellar lines typically requires 25–30 units of Letybo to achieve the same clinical effect. This difference reflects distinct manufacturing processes and potency assay standards, not a product defect.

How long does it take for Letybo to work compared to Botox?

Botox shows visible softening within 3–5 days and reaches full effect by day 10–14, while Letybo typically begins working at 5–7 days with plateau effect by day 14–21. This modest difference is important for setting accurate patient expectations, especially if switching between products.

Is Letybo cheaper than Botox for medspa practices?

Letybo's wholesale cost is typically 15–25% lower per unit than Botox, but because you need 25% more units to match efficacy, the total-dose material cost advantage narrows to roughly 5–10%. Additionally, Letybo lacks rebate programs like Allergan's Alle or Galderma's Aspire, which can further offset pricing for high-volume practices.

Can I switch my patients from Botox to Letybo mid-cycle?

Switching mid-cycle is risky because Letybo's slower onset and different potency may cause patients to perceive delayed or diminished results, leading to dissatisfaction. If you switch, use transparent communication, adjust dosing upward, and consider a trial period so patients understand the difference.

Is Letybo FDA-approved and safe to use?

Yes, Letybo is FDA-cleared via the 510(k) pathway for glabelral lines, crow's feet, and forehead lines—the same approved indications as Botox. It is not a compounded or gray-market product and is available through licensed wholesalers, though supply can be tighter than Botox during peak demand.

What is the difference in diffusion between Letybo and Botox?

Botox has a well-characterized, relatively tight diffusion zone due to its formulation and protein complex, while Letybo's diffusion is comparable but not identical. This subtle difference can affect spread into adjacent musculature, particularly when treating near the orbital rim or brow.

Free weekly brief

Get the free weekly brief.

The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never be the last to know. Cancel anytime.
The daily intelligence brief Go Pro · $20/mo